CYCN News & Events

Cyclerion Therapeutics announced it has received positive written regulatory feedback and responses from the FDA on CYC-126's Phase 2 POC study in TRD and its path to potential regulatory approval. CYC-126 is a potentially novel anesthetic-based investigational therapy that incorporates real-time electroencephalogram feedback and is being developed for the treatment of TRD. CYC-126 is designed to be an individualized, precision-delivered approach that combines well-characterized anesthetic agents with real-time EEG monitoring and algorithm-guided dosing. Cyclerion believes this strategy may enable clinicians to more precisely guide patients toward targeted brain states associated with antidepressant effects, addressing a significant unmet need for patients with TRD seeking alternative therapeutic options.

Cyclerion Therapeutics announced an application-specific, exclusive collaboration with Medsteer. The new collaboration agreement expands upon the parties' existing development collaboration and is intended to enable the integration of Medsteer's technology and know-how into Cyclerion's lead program, CYC-126. CYC-126 is an anesthetic-based investigational therapy that incorporates real-time patient feedback and is currently being developed for the treatment of treatment-resistant depression. Cyclerion remains on track to complete device integration and finalize its proprietary drug delivery system ahead of the planned initiation of the Phase 2 POC study of CYC-126 in the second half of 2026. The company expects to leverage primarily FDA-cleared device components, together with the Medsteer strategic partnership and the previously announced MIT license, with the company's own fit-for-purpose improvements, to support full device build prior to the Phase 2 POC start this year.

Cyclerion Therapeutics announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology, securing the intellectual property that will serve as the cornerstone of its strategic relaunch. This agreement marks a milestone in Cyclerion's transformation into a new company focused on delivering therapies for neuropsychiatric conditions with large unmet needs, beginning with treatment-resistant depression. Cyclerion's lead program leverages common anesthetic agents and a proprietary, tech-driven system to resynchronize communication between key brain regions and restore functional connectivity in patients with TRD. A Phase 2 proof-of-concept trial for its lead program is expected to initiate in 2026, with an initial data set anticipated in 2027. In addition to its lead program, Cyclerion is actively exploring expansion into other neuropsychiatric diseases.